Nventa strengthens patent portfolio with two new European Patents for HPV-related diseases
Patent Number EP 1,296,711 B1, "HPV E7 For Human Papilloma Virus Treatment," covers the use of Nventa's HPV-16 based CoVal(TM) fusion protein HspE7, for the treatment of HPV-related diseases not caused by HPV-16. The patent addresses and provides Nventa protection around observations made from earlier studies that show clinically relevant responses in diseases such as genital warts.
Patent Number EP 1,336,621 B1, "Immune Responses Against HPV Antigens Elicited by Compositions Comprising HPV Antigens and Stress Proteins or an Expression Vector Capable of Expression of These Proteins," provides further coverage for HspE7 with specific claims for the composition of Hsp-HPV E7 fusion proteins and their use for manufacturing drugs that induce an immune response against HPV protein antigens.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.